The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Boehringer Ingelheim; Eisai; GlaxoSmithKline; Novartis; Pfizer; Roche/Genentech
Research Funding - AB Science; Abbvie; Abraxis BioScience; Amgen; Asana Biosciences; Astellas Pharma; AstraZeneca; Biomarin; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Exelixis; GlaxoSmithKline; ImClone Systems; LEO Pharma; Lilly; Medivation; Merck; Merrimack; Millennium; Mylan; Novartis; Pfizer; Roche/Genentech; Sanofi; Taiho Pharmaceutical
 
Travel, Accommodations, Expenses - Roche
KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.
 
Javier Cortes
Stock and Other Ownership Interests - MedSIR
Honoraria - Celgene; Daiichi Sankyo; Eisai; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Samsung
Consulting or Advisory Role - AstraZeneca; Athenex; Bioasis; Biothera; Celgene; Cellestia Biotech; Clovis Oncology; Daiichi Sankyo; ERYTECH Pharma; GlaxoSmithKline; Leuko; Lilly; Merck Sharp & Dohme; Merus; Polyphor; Roche; Seagen; SERVIER
Research Funding - ARIAD (Inst); AstraZeneca (Inst); Baxalta (Inst); Bayer (Inst); Eisai (Inst); Guardant Health (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Piqur (Inst); Puma Biotechnology (Inst); Queen Mary university of London (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo; Eisai; Novartis; Pfizer; Roche
 
David W. Cescon
Honoraria - Novartis; Pfizer
Consulting or Advisory Role - Agendia; AstraZeneca; Genomic Health; GlaxoSmithKline; Merck; Novartis; Pfizer; Puma Biotechnology; Roche/Genentech
Research Funding - GlaxoSmithKline (Inst); Merck (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Patent pending - Biomarkers of TTK inhibitors (assigned to institution)
 
Hope S. Rugo
Consulting or Advisory Role - Celltrion; Ionis Pharmaceuticals
Research Funding - Daiichi Sankyo (Inst); Eisai (Inst); Genentech (Inst); Immunomedics (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Novartis (Inst); OBI Pharma (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Daiichi Sankyo; Macrogenics; Merck; Mylan; Novartis; OBI Pharma; Pfizer; Puma Biotechnology
 
Zbigniew Nowecki
No Relationships to Disclose
 
Seock-Ah Im
Consulting or Advisory Role - Amgen; AstraZeneca; Eisai; Hanmi; Lilly; medpacto; Novartis; Pfizer; Roche/Genentech
Research Funding - AstraZeneca; Pfizer; Roche/Genentech
Travel, Accommodations, Expenses - Novartis; Roche/Genentech
Other Relationship - Roche
 
Mastura Md Yusof
No Relationships to Disclose
 
Carlos Gallardo
Consulting or Advisory Role - Lilly; MSD; Roche
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - Novartis; Roche
Travel, Accommodations, Expenses - MSD; Roche
 
Oleg Lipatov
No Relationships to Disclose
 
Carlos Henrique Barrios
No Relationships to Disclose
 
Esther Holgado
No Relationships to Disclose
 
Hiroji Iwata
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Lilly Japan; Novartis; Pfizer
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly Japan; Novartis; Pfizer
Research Funding - AstraZeneca (Inst); Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Pfizer (Inst)
 
Norikazu Masuda
Leadership - Japan Breast Cancer Research Group
Honoraria - AstraZeneca; Chugai Pharma; Eisai; Lilly Japan; Pfizer; Takeda
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst)
 
Marco Torregroza Otero
No Relationships to Disclose
 
Erhan Gokmen
Honoraria - Janssen Oncology; Lilly; Novartis; Pfizer; Roche
Consulting or Advisory Role - Lilly; Novartis; Pfizer; Roche
Speakers' Bureau - Lilly; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD Oncology; Novartis; Pfizer; Roche
 
Sherene Loi
Consulting or Advisory Role - Aduro Biotech (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); G1 Therapeutics (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst)
Research Funding - Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst); Seagen (Inst)
 
Zifang Guo
Employment - Merck
Stock and Other Ownership Interests - Genmab (I); Merck
Patents, Royalties, Other Intellectual Property - Merck
 
Jing Zhao
Employment - Merck
Stock and Other Ownership Interests - Merck
Travel, Accommodations, Expenses - Merck
 
Gursel Aktan
Employment - Merck; Merck (I)
Stock and Other Ownership Interests - Merck; Merck (I)
Travel, Accommodations, Expenses - Merck; Merck (I)
 
Vassiliki Karantza
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Peter Schmid
Employment - Genentech (I); Roche (I)
Honoraria - AstraZeneca; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Celgene; Eisai; Genentech/Roche (I); Merck; Novartis; Pfizer; Puma Biotechnology
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Genentech (Inst); Novartis (Inst); Oncogenex (Inst); Roche (Inst)